According to the National Institutes of Health (NIH), approximately 60 to 70 million people in the U.S. are affected by some type of digestive disease.² With so many affected people and an estimated cost of $141.8 billion in the U.S., the unmet need to help diagnose and care for these patients is clear.²

Metabolomics can reveal actionable insights about state of health offering tremendous value to understanding disease susceptibility. Precision Metabolomics™ is an essential technology for investigating the interplay of genetics, diet and the microbiome in health maintenance and particularly in complex, multifactorial diseases of the digestive tract.

Measuring the small molecules that serve as signals between microbial communities and the host has enabled a functional understanding of gut microbial activity. Metabolon deciphers thousands of discrete chemical signals and connects them in biological pathways that are not captured by other ‘omics, providing a definitive representation of the phenotype.

Understanding the underlying biology of chronic diseases, like IBS, is important in identifying biomarkers that will enable disease prevention, detection, and optimal treatment efficacy. With our industry-leading library of over 5200 metabolites, Metabolon has the broadest coverage and capability to see potential biomarkers in your data. Combined with 20+ years of experience and our team of expert systems biologists, we are able to work more effectively together with you to design a biomarker-focused study that accelerates discovery, avoids roadblocks and provides the necessary actionable information for progressing your research.

1. International Foundation for Functional Gastrointestinal Disorders. Facts about IBS. Available at http://www.aboutibs.org/what-is-ibs/facts-about-ibs-2.html. Accessed 04-11-2017.

2. National Institute of Health. Digestive Diseases Statistics for the United States. Available at https://www.niddk.nih.gov/health-information/health-statistics/digestive-diseases. Accessed 06-02-2020.